Changeflow GovPing Healthcare & Life Sciences Patent Application for Detecting Immune Cells U...
Routine Notice Added Draft

Patent Application for Detecting Immune Cells Using Fusion Proteins

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085104A1) detailing fusion proteins for detecting and isolating immune cells. The application, filed by Patrick Schlegel, describes specific fusion proteins involving a dysfunctional purinergic P2X7 receptor epitope and an antibody Fc region.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO, specifically application number US20260085104A1, filed on September 14, 2023. It describes methods and fusion proteins for detecting and isolating immune cells, particularly those involving a dysfunctional purinergic P2X7 receptor epitope moiety and an antibody Fc region. The application is classified under CPC codes related to protein chemistry and immunological assays.

As this is a patent application, it does not impose immediate regulatory requirements or compliance deadlines on entities. However, it signals potential future intellectual property and innovation in the field of immune cell detection and isolation. Companies involved in biotechnology, diagnostics, and pharmaceutical research should be aware of this filing as it may impact their own research and development efforts or patent strategies.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS OF DETECTING IMMUNE CELLS

Application US20260085104A1 Kind: A1 Mar 26, 2026

Inventors

Patrick Schlegel

Abstract

The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moiety and a Fc region of an antibody.

CPC Classifications

C07K 14/705 G01N 33/532 G01N 33/56972 C07K 2319/30 G01N 2333/705

Filing Date

2023-09-14

Application No.

19110332

View original document →

Named provisions

Inventors Abstract CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 14th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085104A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Immune Cell Isolation Biotechnology Research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Biotechnology Medical Research

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!